Akso Health Group has started a new research and development program focused on next-generation brain-computer interface (BCI) technology, aiming to create innovations in neural sensing, AI neural decoding, and interface design. This initiative is intended to build a long-term growth engine for the company by addressing unmet needs in neuroscience, therapeutics, and human-machine interaction. The company has not yet begun human trials or regulatory submissions and cautions that product development and commercialization are uncertain. Akso Health currently operates in medical device sales and online medical consultations in China and the US.
Grab's Chief Product Officer has sold 30,000 shares, generating $109,200 from the transaction. This insider sale may indicate personal financial planning or a strategic move, but it does not necessarily reflect the company's overall performance. Inve...
Hyperliquid's AQA v2 model forecasts $193 million in annual revenue and $527,000 daily buybacks of its HYPE token in 2026, signaling strong financial health. This projection has increased market confidence, raising the odds of Hyperliquid reaching $1...
Bitcoin's price has hovered near $80,000 with no clear direction as long-term holders (OGs) increase selling, signaling potential profit-taking. Data shows a spike in Bitcoin moved by holders with assets over five years, indicating some weakening con...
BNB Chain announced it will no longer prioritize reducing gas fees, which it had aggressively cut by over 90% in recent years. Instead, the network aims to develop sustainable business models involving gas fees, revenue sharing, and commercial agreem...
Bitcoin's price recently hovered between $76,200 and $82,100, sparking bullish sentiment in the market. Eleven AI models were asked to predict Bitcoin's year-end 2026 price, with forecasts ranging from $84,500 to $105,480. The median prediction is ar...
